WuXi Biologics' MFG5 facility completes first GMP production at 24,000-L line
The facility's total 60,000-L capacity supports growing demand for manufacture of late-phase and commercial projects
Building on the success of intiating GMP operations of the 36,000-L biomanufacturing line of its drug substance facility MFG5 in February this year, China's WuXi Biologics has now completed the first GMP production at the facility's new 24,000-L line.
The new line combines 12 x 2000-L single-use bioreactors to enable various production processes — including fed-batch, perfusion and concentrated fed-batch — at different scales, ranging from 2,000 L to 12,000 L.
According to the company, implementing WuXiUP ― a continuous manufacturing bioprocessing platform based on intensified perfusion culture processes ― in the 24,000-L line for commercial production will allow MFG5 to increase productivity and reduce cost of goods sold.
Now, with its total 60,000-L capacity, MFG5 will further support growing demand for the manufacture of late-phase and commercial projects across multiple modalities, such as monoclonal antibodies, bispecifics and fusion proteins, the company said.
As a result, there is a total of approximately 150,000L biomanfacturing capacity at WuXi Biologics, which makes the company one of the largest cGMP biologics manufacturing facilities in the world to employ only single-use bioreactors.
Dr Chris Chen, CEO of WuXi Biologics said the rapidly growing demand from global companies for commercial manufacturing is due to the "success of our ‘follow and win-the-molecule’ strategy".
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance